INVESTOR AGREEMENTInvestor Agreement • November 5th, 2020 • Solid Biosciences Inc. • Biological products, (no disgnostic substances) • Delaware
THIS INVESTOR AGREEMENT (this “Agreement”) is made as of October 22, 2020, by and between Solid Biosciences Inc., a Delaware corporation (the “Company”), and Ultragenyx Pharmaceutical Inc., a Delaware corporation (the “Investor”).
COLLABORATION AND LICENSE AGREEMENT BETWEEN ULTRAGENYX PHARMACEUTICAL INC. AND SOLID BIOSCIENCES INC. October 22, 2020Collaboration and License Agreement • November 5th, 2020 • Solid Biosciences Inc. • Biological products, (no disgnostic substances) • New York
FIRST AMENDMENT TO THE EXCLUSIVE PATENT LICENSEPatent License • November 5th, 2020 • Solid Biosciences Inc. • Biological products, (no disgnostic substances)
This First Amendment dated as of October 9, 2020 (the “Amendment”) is made to that Exclusive Patent License between Solid Biosciences Inc. (“Solid”) and the University of Washington acting through UW CoMotion (“University”) dated as of October 16, 2015 with a University reference number 37475A (the “Agreement”). Capitalized terms used herein and not defined have the meaning as set forth in the Agreement.
STOCK PURCHASE AGREEMENT By and Between SOLID BIOSCIENCES INC. AND ULTRAGENYX PHARMACEUTICAL INC. Dated as of October 22, 2020Stock Purchase Agreement • November 5th, 2020 • Solid Biosciences Inc. • Biological products, (no disgnostic substances) • Delaware
THIS STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of October 22, 2020 (the “Effective Date”), is entered into by and between Solid Biosciences Inc., a Delaware corporation (the “Company”), and Ultragenyx Pharmaceutical Inc., a Delaware corporation (the “Investor”). The Investor and the Company are referred to herein collectively as the “Parties”.
